SPECT/CT perfusion imaging for Peripheral Arterial Disease

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Peripheral Arterial Disease+4 More
SPECT/CT perfusion imaging - DiagnosticTest
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial will test whether radiotracer-based perfusion imaging can help predict clinical outcomes for diabetic patients with PAD undergoing lower extremity revascularization procedures.

Eligible Conditions
  • Peripheral Arterial Disease
  • Diabetes Mellitus
  • Ischemia

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 2 Secondary · Reporting Duration: 1 year

1 year
Limb salvage
Wound healing
1-2 weeks
Lower extremity perfusion

Trial Safety

Safety Progress

1 of 3

Trial Design

2 Treatment Groups

PET/CT perfusion imaging
1 of 2
SPECT/CT perfusion imaging
1 of 2
Experimental Treatment

200 Total Participants · 2 Treatment Groups

Primary Treatment: SPECT/CT perfusion imaging · No Placebo Group · N/A

PET/CT perfusion imagingExperimental Group · 2 Interventions: PET/CT perfusion imaging, SPECT/CT perfusion imaging · Intervention Types: DiagnosticTest, DiagnosticTest
SPECT/CT perfusion imagingExperimental Group · 2 Interventions: PET/CT perfusion imaging, SPECT/CT perfusion imaging · Intervention Types: DiagnosticTest, DiagnosticTest

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 1 year

Who is running the clinical trial?

Nationwide Children's HospitalLead Sponsor
305 Previous Clinical Trials
5,209,842 Total Patients Enrolled
Ohio State UniversityOTHER
704 Previous Clinical Trials
382,103 Total Patients Enrolled
Mitchel R Stacy, Ph.D.Principal InvestigatorNationwide Children's Hospital

Eligibility Criteria

Age 18+ · All Participants · 2 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
This means that you must be at least 18 years old in order to purchase a firearm.
There is significant obstructive disease in one or more lower extremity arteries, as shown by a prior ABI, TBI, CT angiography, ultrasound, or MR imaging.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 15th, 2021

Last Reviewed: October 8th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.

References